Safety and Tolerability of Omecamtiv Mecarbil During Exercise in Patients With Ischemic Cardiomyopathy and Angina

This publication has 14 references indexed in Scilit:

• Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study
  The Lancet, 2011
• The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial
  The Lancet, 2011
• Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure
  Science, 2011
• Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond
  Heart Failure Reviews, 2009
• Inotropes in the management of acute heart failure
  Critical Care Medicine, 2008
• ACC/AHA 2002 guideline update for exercise testing: summary article
  JACC, 2002
• Short-term Intravenous Milrinone for Acute Exacerbation of Chronic Heart FailureA Randomized Controlled Trial
  JAMA, 2002
• A Dose-Dependent Increase in Mortality with Vesnarinone among Patients with Severe Heart Failure
  New England Journal of Medicine, 1998
• Effect of Oral Milrinone on Mortality in Severe Chronic Heart Failure
  New England Journal of Medicine, 1991
• Long-Term Vasodilator Therapy with Trimazosin in Chronic Cardiac Failure
  New England Journal of Medicine, 1980